PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
October 1, 2025Open Access

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMark LebwohlDRDarrell S. RigelZEZeynep Eroglu

Discussion

Loading...

Member takes

Overview

Longitudinal analysis reveals treatment patterns in patients with basal cell carcinoma, suggesting differences between sonidegib and vismodegib.

Key Points

  • Sonidegib-treated patients remained on treatment longer than those on vismodegib, demonstrating improved adherence.
  • Patients receiving sonidegib were 23% and 32% less likely to discontinue treatment at 6 and 9 months, respectively.
  • Patients on sonidegib experienced fewer gastrointestinal-related conditions, highlighting a potential safety advantage.
  • Real-world data from the Komodo Health Claims Database suggests significant differences in treatment outcomes.

Cite This Study

Lebwohl et al. (2025) studied this question.

synapsesocial.com/papers/68dd91cbfe798ba2fc4988b4https://doi.org/10.1101/2025.09.29.25336664
View Full Paper
Ask AI
Bookmark
Share